AU2003279877B2 - Modulation of anxiety through blockade of anandamide hydrolysis - Google Patents

Modulation of anxiety through blockade of anandamide hydrolysis Download PDF

Info

Publication number
AU2003279877B2
AU2003279877B2 AU2003279877A AU2003279877A AU2003279877B2 AU 2003279877 B2 AU2003279877 B2 AU 2003279877B2 AU 2003279877 A AU2003279877 A AU 2003279877A AU 2003279877 A AU2003279877 A AU 2003279877A AU 2003279877 B2 AU2003279877 B2 AU 2003279877B2
Authority
AU
Australia
Prior art keywords
compound
unsubstituted
substituted
faah
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003279877A
Other languages
English (en)
Other versions
AU2003279877A1 (en
Inventor
Andrea Duranti
Marco Mor
Daniele Piomelli
Georgio Tarzia
Andrea Tontini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Parma
Universita degli Studi di Urbino "Carlo Bo"
University of California San Diego UCSD
Original Assignee
Degli Studi Di Parma, University of
Universita degli Studi di Parma
Universita degli Studi di Urbino "Carlo Bo"
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degli Studi Di Parma, University of, Universita degli Studi di Parma, Universita degli Studi di Urbino "Carlo Bo", University of California Berkeley, University of California San Diego UCSD filed Critical Degli Studi Di Parma, University of
Publication of AU2003279877A1 publication Critical patent/AU2003279877A1/en
Application granted granted Critical
Publication of AU2003279877B2 publication Critical patent/AU2003279877B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AU2003279877A 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis Ceased AU2003279877B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41700802P 2002-10-07 2002-10-07
US60/417,008 2002-10-07
PCT/US2003/031844 WO2004033422A2 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis

Publications (2)

Publication Number Publication Date
AU2003279877A1 AU2003279877A1 (en) 2004-05-04
AU2003279877B2 true AU2003279877B2 (en) 2010-05-20

Family

ID=32093946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003279877A Ceased AU2003279877B2 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis

Country Status (11)

Country Link
US (3) US7176201B2 (enExample)
EP (1) EP1558591B1 (enExample)
JP (1) JP4515911B2 (enExample)
KR (1) KR20050088992A (enExample)
CN (1) CN100408556C (enExample)
AU (1) AU2003279877B2 (enExample)
CA (1) CA2501506C (enExample)
EA (1) EA010267B1 (enExample)
MX (1) MXPA05003715A (enExample)
UA (1) UA80841C2 (enExample)
WO (1) WO2004033422A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
JP4943837B2 (ja) * 2003-04-03 2012-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良インヒビター
EP1677780A4 (en) * 2003-10-16 2007-05-02 Univ California DIETARY AND OTHER FOODS, COMPOUNDS AND METHOD FOR REDUCING BODY FAT, APPETIZING AND MODULATING THE FATTY ACID CHANGES
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
JP4427578B2 (ja) * 2004-06-23 2010-03-10 エフ．ホフマン−ラ ロシュ アーゲー 新規ｍａｏ−ｂインヒビター
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
EP1814875A4 (en) * 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
WO2006058088A2 (en) * 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
SI2607362T1 (sl) 2005-02-17 2015-03-31 Astellas Pharma Inc. Piperidinski in piperazinski karboksilati kot FAAH inhibitorji
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
JP2009522287A (ja) * 2005-12-29 2009-06-11 ナームローゼ・フエンノートチヤツプ・オルガノン 脂肪酸アミド加水分解酵素阻害剤
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
WO2007106706A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders
EP2023728A4 (en) * 2006-05-26 2010-11-24 Janssen Pharmaceutica Nv OXAZOLYLPIPERIDINES AS MODULATORS OF FATTY ACID AMIDHYDROLASE
CA2661085A1 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
US7888394B2 (en) * 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008042892A2 (en) * 2006-10-02 2008-04-10 N.V. Organon Fatty acid amide hydrolase inhibitors for energy metabolism disorders
US20080119549A1 (en) * 2006-11-20 2008-05-22 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
DE102007022007A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
EP2152082B1 (en) * 2007-05-25 2012-08-29 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
CA2689148A1 (en) * 2007-05-31 2008-12-11 The Scripps Research Institute Tricyclic inhibitors of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
TWI434842B (zh) 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
BRPI0921692A2 (pt) 2008-11-06 2018-06-26 Astellas Pharma Inc composto carbamato ou o sal do mesmo
FR2938537B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
BRPI0923819B1 (pt) * 2008-12-24 2021-11-09 Bial-Portela & Ca, S.A. Compostos inibidores de hidrolase amida de ácidos graxos, composições e usos dos mesmos
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
CA2773590C (en) 2009-09-09 2017-09-05 Keiji Adachi 8-oxodihydropurine derivative
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
RU2012135525A (ru) * 2010-01-20 2014-02-27 Санофи Производные алкилгетероциклических карбаматов, их получение и применение в терапии
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
EP2593078B1 (en) 2010-05-25 2016-11-30 Symrise AG Cyclohexyl carbamate compounds as active anti-cellulite ingredients
JP5838498B2 (ja) * 2010-05-25 2016-01-06 シムライズ アーゲー 皮膚及び／又は毛髪のライトニング活性物質としてのシクロヘキシルカルバメート化合物
JP5981429B2 (ja) * 2010-07-28 2016-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 末梢に制限されたｆａａｈ阻害剤
PT2433527E (pt) * 2010-09-28 2013-04-30 Gruppo Cimbali Spa Varinha automática melhorada de produção de espuma de leite
WO2013028570A2 (en) 2011-08-19 2013-02-28 The Regents Of The University Of California Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
EP3022179B1 (en) 2013-07-18 2017-11-15 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
AR100387A1 (es) * 2014-02-18 2016-10-05 Basf Se Copolímeros que comprenden etileno, ésteres de vinilo y ésteres de ácido (met)acrílico, sus formulaciones y usos como depresor del punto de fluidez, inhibidor de cera y potenciador de flujo para petróleos crudos
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
EP3303289A4 (en) * 2015-06-05 2018-11-14 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
TW201733620A (zh) 2015-12-11 2017-10-01 國立大學法人靜岡大學 油凝膠化劑
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
EP3762034B1 (en) 2018-03-05 2025-08-27 Wylder Nation Foundation A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
EP4243811A4 (en) * 2020-07-21 2025-04-16 Neuritek Ltd. USES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS ASSOCIATED WITH TRAUMA
WO2025015420A1 (en) * 2023-07-17 2025-01-23 Apogee Pharmaceuticals, Inc. Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531554A (enExample) * 1953-09-02
US3084096A (en) * 1955-08-29 1963-04-02 Union Carbide Corp Indanyl n-methyl carbamate
US3275512A (en) 1962-11-27 1966-09-27 Upjohn Co Process for treating inflammation with biphenylcarbamates
US3632631A (en) 1967-09-08 1972-01-04 Ethyl Corp Sterically hindered bisphenyl carbamates
US3880908A (en) 1972-01-24 1975-04-29 Standard Oil Co Urethane derivatives of polymethyl biphenyl useful as fungicides
DE2943480A1 (de) * 1979-10-27 1981-05-07 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n,o-disubstituierten urethanen, sowie ihre verwendung als ausgangsmaterial zur herstellung von isocyanaten
HU197831B (en) 1984-12-20 1989-06-28 Chinoin Gyogyszer Es Vegyeszet Insecticide compositions containing alkenyl-oxy-phenyl-carbamat derivatives as active components and process for producing the active components
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
JPS63303661A (ja) 1987-01-22 1988-12-12 Ishikawajima Harima Heavy Ind Co Ltd 注湯装置
US4987233A (en) * 1988-06-15 1991-01-22 Eli Lilly And Company Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives
IL95994A0 (en) * 1989-11-15 1991-07-18 American Home Prod Carbamate esters and pharmaceutical compositions containing them
US5112859A (en) * 1990-09-14 1992-05-12 American Home Products Corporation Biphenyl amide cholesterol ester hydrolase inhibitors
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
DE69314148T2 (de) 1992-12-17 1998-01-15 Valeo Systemes Essuyage Stromversorgungsverfahren und -vorrichtung für einen elektrischen Motor zum Antrieb eines Scheibenwischers eines Kraftfahrzeugs
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
DE4430600A1 (de) * 1994-08-22 1996-02-29 Hoechst Schering Agrevo Gmbh Biphenyl-Derivate
JPH0892167A (ja) * 1994-09-21 1996-04-09 Idemitsu Kosan Co Ltd 芳香族炭酸ジエステルの製造方法
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
KR20000069028A (ko) * 1996-11-19 2000-11-25 와트 씨 데이빗, 해리 에이 루스제 피리도스티그민의 다가염 및 관련 화합물
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
BR0112655A (pt) 2000-07-19 2003-06-24 Hoffmann La Roche Derivados de pirrolidino como inibidores de metaloproteases
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR100566175B1 (ko) * 2000-08-16 2006-03-29 에프. 호프만-라 로슈 아게 신규한 아미노사이클로헥산 유도체
ATE348829T1 (de) 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
EP1389107A4 (en) * 2001-04-27 2005-10-12 Bristol Myers Squibb Co BISARYLIMIDAZOLYL-FATTY ACID AMIDE-HYDROLASE INHIBITORS
AU2002351731A1 (en) 2001-12-14 2003-06-30 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
AU2003210824A1 (en) * 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis

Also Published As

Publication number Publication date
US8003693B2 (en) 2011-08-23
US7176201B2 (en) 2007-02-13
CA2501506A1 (en) 2004-04-22
CN1729171A (zh) 2006-02-01
EA010267B1 (ru) 2008-06-30
CN100408556C (zh) 2008-08-06
KR20050088992A (ko) 2005-09-07
MXPA05003715A (es) 2005-09-30
US20120010283A1 (en) 2012-01-12
EP1558591A2 (en) 2005-08-03
WO2004033422A3 (en) 2004-07-29
US20040127518A1 (en) 2004-07-01
CA2501506C (en) 2014-02-11
AU2003279877A1 (en) 2004-05-04
EP1558591B1 (en) 2014-05-07
US20090048337A1 (en) 2009-02-19
WO2004033422A2 (en) 2004-04-22
UA80841C2 (en) 2007-11-12
EA200500615A1 (ru) 2005-10-27
EP1558591A4 (en) 2007-09-12
JP4515911B2 (ja) 2010-08-04
JP2006511484A (ja) 2006-04-06

Similar Documents

Publication Publication Date Title
AU2003279877B2 (en) Modulation of anxiety through blockade of anandamide hydrolysis
US20240335418A1 (en) Safer psychoactive compositions
Kathuria et al. Modulation of anxiety through blockade of anandamide hydrolysis
WO2008024139A2 (en) Inhibitors of fatty acid amide hydrolase
US12221428B2 (en) Use of deuterated empathogens as therapeutic agents
KR20130110160A (ko) 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
WO2012167133A2 (en) Inhibitors of anandamide transport and their therapeutic uses
EP1969051A2 (en) Inhibitors of fatty acid amide hydrolase
Silakari et al. Systematic in silico design, synthesis, and biological studies of some novel 1, 4-benzoquinone derivatives for the prospective management of cognitive decline
JP2011518188A (ja) リソソーム調節のための化合物および使用方法
EP4400494A1 (en) Novel compound and use thereof for treating emotional behavioral disorders
WO2025019403A2 (en) Substituted amino-phenylmethylene-imidazolones
EA019496B1 (ru) Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
EP4504187A1 (en) T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof
EP4392027A2 (en) Fluorinated empathogens
NZ622480B2 (en) Meta-substituted biphenyl peripherally restricted faah inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired